New peripheral artery group in Germany
This article was originally published in Clinica
Executive Summary
A group of 15 German companies that specialise in peripheral artery medicine have set up their own dedicated interest group. The FBPG (Periphere Gefassmedizin) group, founded within the Berlin-based industry association BVMed, has two principal motives: ensuring that the products and procedures of this division of the medtech industry are properly represented within the diagnosis-related groups (DRGs); and setting up a treatment record for research purposes. This would entail the establishment of a prospective register of percutaneous transluminal angioplasty (PTA) procedures, which would record post-surgical observations of patients suffering from peripheral occlusive arterial disease, pre- or post-PTA. This would be done in co-operation with three medical expert societies.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.